Κυριακή 14 Ιανουαρίου 2018

A Potential Cure for Genetic Deafness

​Researchers from the Howard Hughes Medical Institute have successfully prevented genetic hearing loss in mice through the genome editing technology CRISPR-Cas9 in a recent study. (Nature 2017. doi: 10.1038/nature25164. [Epub ahead of print].) They injected a single treatment of a genome editing cocktail, which acted as molecular scissors and disrupted the mutation in the gene Tmc1, into the inner ears of infant mice with that mutation. The hair cells in treated ears resembled those in healthy animals after eight weeks, and treated ears could hear sounds about 15 dB lower than untreated ears. 

                                                       cas9-1.jpg

Scientists can gauge mouse hearing by measuring how much noise (dB SPL) it takes to trigger an auditory brainstem response (ABR). Sounds starting at roughly 30 decibels can spark brain activity in normal mice (green/bottom line). Mice with the Tmc1 mutation lose their ability to hear and eventually become deaf. But injecting their inner ears with a genome editing agent made them more sensitive to sound (blue/middle line) than ears without an injection (red/top line). Credit: X. Gao, et al./Nature 2017 (http://bit.ly/2CZXbdR). 

A single spelling error in Tmc1causes the loss of the inner ear's hair cells over time, and just one copy of a mutated Tmc1 gene causes progressive hearing loss leading to profound deafness in both humans and mice. Scientists at Howard Hughes snipped both strands of the DNA double helix with Cas9 to disable the gene. The challenge of the study lied in directing Cas9 to only the bad copy of Tmc1 and not the good one because the two copies differ by just one DNA letter. Researchers in this study packaged Cas9 and the guiding RNA into a greasy bundle that slips inside cells but doesn't stick around, allowing Cas9 to hit the bad gene copy and fade away before it could harm the good one. 

cas9-2.gif       cas9-2.gif

In the genome editing technology known as CRISPR-Cas9, RNA (blue) guides the protein Cas9 (large bumpy structure) to a target site in DNA (red). Cas9 unwinds the DNA double helix and acts as molecular scissors, snipping both strands of DNA. This animation is a preview of an interactive web feature that HHMI BioInteractive will debut in March of 2018. Credit: Howard Hughes Medical Institute (http://bit.ly/2CZXbdR).

​David Liu, PhD, a professor of chemistry and chemical biology at Harvard University and an investigator in the study, said the work is among the first to apply a genome editing approach to deafness in animals, and the positive change they observed in the mice could make a major difference in the quality of life for patients with hearing loss. "We hope that the work will one day inform the development of a cure for certain forms of genetic deafness in people," he said. 


Published: 1/14/2018 2:13:00 PM


from #Audiology via ola Kala on Inoreader http://ift.tt/2D5kkZm
via IFTTT

A Potential Cure for Genetic Deafness

​Researchers from the Howard Hughes Medical Institute have successfully prevented genetic hearing loss in mice through the genome editing technology CRISPR-Cas9 in a recent study. (Nature 2017. doi: 10.1038/nature25164. [Epub ahead of print].) They injected a single treatment of a genome editing cocktail, which acted as molecular scissors and disrupted the mutation in the gene Tmc1, into the inner ears of infant mice with that mutation. The hair cells in treated ears resembled those in healthy animals after eight weeks, and treated ears could hear sounds about 15 dB lower than untreated ears. 

                                                       cas9-1.jpg

Scientists can gauge mouse hearing by measuring how much noise (dB SPL) it takes to trigger an auditory brainstem response (ABR). Sounds starting at roughly 30 decibels can spark brain activity in normal mice (green/bottom line). Mice with the Tmc1 mutation lose their ability to hear and eventually become deaf. But injecting their inner ears with a genome editing agent made them more sensitive to sound (blue/middle line) than ears without an injection (red/top line). Credit: X. Gao, et al./Nature 2017 (http://bit.ly/2CZXbdR). 

A single spelling error in Tmc1causes the loss of the inner ear's hair cells over time, and just one copy of a mutated Tmc1 gene causes progressive hearing loss leading to profound deafness in both humans and mice. Scientists at Howard Hughes snipped both strands of the DNA double helix with Cas9 to disable the gene. The challenge of the study lied in directing Cas9 to only the bad copy of Tmc1 and not the good one because the two copies differ by just one DNA letter. Researchers in this study packaged Cas9 and the guiding RNA into a greasy bundle that slips inside cells but doesn't stick around, allowing Cas9 to hit the bad gene copy and fade away before it could harm the good one. 

cas9-2.gif       cas9-2.gif

In the genome editing technology known as CRISPR-Cas9, RNA (blue) guides the protein Cas9 (large bumpy structure) to a target site in DNA (red). Cas9 unwinds the DNA double helix and acts as molecular scissors, snipping both strands of DNA. This animation is a preview of an interactive web feature that HHMI BioInteractive will debut in March of 2018. Credit: Howard Hughes Medical Institute (http://bit.ly/2CZXbdR).

​David Liu, PhD, a professor of chemistry and chemical biology at Harvard University and an investigator in the study, said the work is among the first to apply a genome editing approach to deafness in animals, and the positive change they observed in the mice could make a major difference in the quality of life for patients with hearing loss. "We hope that the work will one day inform the development of a cure for certain forms of genetic deafness in people," he said. 


Published: 1/14/2018 2:13:00 PM


from #Audiology via ola Kala on Inoreader http://ift.tt/2D5kkZm
via IFTTT

A Potential Cure for Genetic Deafness

​Researchers from the Howard Hughes Medical Institute have successfully prevented genetic hearing loss in mice through the genome editing technology CRISPR-Cas9 in a recent study. (Nature 2017. doi: 10.1038/nature25164. [Epub ahead of print].) They injected a single treatment of a genome editing cocktail, which acted as molecular scissors and disrupted the mutation in the gene Tmc1, into the inner ears of infant mice with that mutation. The hair cells in treated ears resembled those in healthy animals after eight weeks, and treated ears could hear sounds about 15 dB lower than untreated ears. 

                                                       cas9-1.jpg

Scientists can gauge mouse hearing by measuring how much noise (dB SPL) it takes to trigger an auditory brainstem response (ABR). Sounds starting at roughly 30 decibels can spark brain activity in normal mice (green/bottom line). Mice with the Tmc1 mutation lose their ability to hear and eventually become deaf. But injecting their inner ears with a genome editing agent made them more sensitive to sound (blue/middle line) than ears without an injection (red/top line). Credit: X. Gao, et al./Nature 2017 (http://bit.ly/2CZXbdR). 

A single spelling error in Tmc1causes the loss of the inner ear's hair cells over time, and just one copy of a mutated Tmc1 gene causes progressive hearing loss leading to profound deafness in both humans and mice. Scientists at Howard Hughes snipped both strands of the DNA double helix with Cas9 to disable the gene. The challenge of the study lied in directing Cas9 to only the bad copy of Tmc1 and not the good one because the two copies differ by just one DNA letter. Researchers in this study packaged Cas9 and the guiding RNA into a greasy bundle that slips inside cells but doesn't stick around, allowing Cas9 to hit the bad gene copy and fade away before it could harm the good one. 

cas9-2.gif       cas9-2.gif

In the genome editing technology known as CRISPR-Cas9, RNA (blue) guides the protein Cas9 (large bumpy structure) to a target site in DNA (red). Cas9 unwinds the DNA double helix and acts as molecular scissors, snipping both strands of DNA. This animation is a preview of an interactive web feature that HHMI BioInteractive will debut in March of 2018. Credit: Howard Hughes Medical Institute (http://bit.ly/2CZXbdR).

​David Liu, PhD, a professor of chemistry and chemical biology at Harvard University and an investigator in the study, said the work is among the first to apply a genome editing approach to deafness in animals, and the positive change they observed in the mice could make a major difference in the quality of life for patients with hearing loss. "We hope that the work will one day inform the development of a cure for certain forms of genetic deafness in people," he said. 


Published: 1/14/2018 2:13:00 PM


from #Audiology via xlomafota13 on Inoreader http://ift.tt/2D5kkZm
via IFTTT

Genotype-phenotype correlations in individuals with pathogenic RERE variants.

Related Articles

Genotype-phenotype correlations in individuals with pathogenic RERE variants.

Hum Mutat. 2018 Jan 13;:

Authors: Jordan VK, Fregeau B, Ge X, Giordano J, Wapner RJ, Balci TB, Carter MT, Bernat JA, Moccia AN, Srivastava A, Martin DM, Bielas SL, Pappas J, Svoboda MD, Rio M, Boddaert N, Cantagrel V, Lewis AM, Scaglia F, Undiagnosed Diseases Network, Kohler JN, Bernstein JA, Dries AM, Rosenfeld JA, DeFilippo C, Thorson W, Yang Y, Sherr EH, Bi W, Scott DA

Abstract
Heterozygous variants in the arginine-glutamic acid dipeptide repeats gene (RERE) have been shown to cause neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH). Here we report nine individuals with NEDBEH who carry partial deletions or deleterious sequence variants in RERE. These variants were found to be de novo in all cases in which parental samples were available. An analysis of data from individuals with NEDBEH suggests that point mutations affecting the Atrophin-1 domain of RERE are associated with an increased risk of structural eye defects, congenital heart defects, renal anomalies and sensorineural hearing loss when compared to loss-of-function variants that are likely to lead to haploinsufficiency. A high percentage of RERE pathogenic variants affect a histidine-rich region in the Atrophin-1 domain. We have also identified a recurrent two-amino-acid duplication in this region that is associated with the development of a CHARGE syndrome-like phenotype. We conclude that mutations affecting RERE result in a spectrum of clinical phenotypes. Genotype-phenotype correlations exist and can be used to guide medical decision making. Consideration should also be given to screening for RERE variants in individuals who fulfill diagnostic criteria for CHARGE syndrome but do not carry pathogenic variants in CHD7. This article is protected by copyright. All rights reserved.

PMID: 29330883 [PubMed - as supplied by publisher]



from #Audiology via xlomafota13 on Inoreader http://ift.tt/2EHODp1
via IFTTT

Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection.

Related Articles

Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection.

Pediatrics. 2018 Jan 12;:

Authors: Gunkel J, de Vries LS, Jongmans M, Koopman-Esseboom C, van Haastert IC, Eijsermans MCJ, van Stam C, van Zanten BGA, Wolfs TFW, Nijman J

Abstract
OBJECTIVES: To assess whether preterm infants with postnatal cytomegalovirus infection develop neurologic sequelae in early childhood.
METHODS: Infants <32 weeks' gestation were prospectively screened for cytomegalovirus (CMV) at term-equivalent age. Neurodevelopment was compared between CMV-positive and CMV-negative infants by using the Griffiths Mental Development Scales (GMDS) at 16 months' corrected age (CA); the Bayley Scales of Infant and Toddler Development, Third Edition or the GMDS at 24 to 30 months' CA; and the Wechsler Preschool and Primary Scale of Intelligence, Third Edition and Movement Assessment Battery for Children, Second Edition at 6 years of age. At 6 years old, hearing was assessed in CMV-positive children.
RESULTS: Neurodevelopment was assessed in 356 infants at 16 months' CA, of whom 49 (14%) were infected and 307 (86%) were noninfected. Infected infants performed significantly better on the GMDS locomotor scale. There were no differences at 24 to 30 months' CA on the Bayley Scales of Infant and Toddler Development, Third Edition or GMDS. At 6 years of age, infected children scored lower on the Wechsler Preschool and Primary Scale of Intelligence, Third Edition, but mean scores were within normal range, reaching significance only in verbal IQ (96 [SD 17] vs 103 [SD 15] points; P = .046). Multiple regression indicated no impact of CMV status but significant influence of maternal education and ethnicity on verbal IQ. No significant differences in motor development were found and none of the infected children developed sensorineural hearing loss.
CONCLUSIONS: In this cohort study, postnatal cytomegalovirus infection in preterm children did not have an adverse effect on neurodevelopment within the first 6 years of life.

PMID: 29330315 [PubMed - as supplied by publisher]



from #Audiology via xlomafota13 on Inoreader http://ift.tt/2EFNui5
via IFTTT